The Oncomine™ Comprehensive Library Assay is a targeted

Thermo Fisher Scientific, University Hospital Basel Launch NGS CDx Partnership

Partners to develop next-generation sequencing-based cancer diagnostics, to accelerate clinical research into oncology and immuno-oncology
The FDA has approved Roche’s VENTANA PD-L1 (SP142) Assay as the first companion diagnostic authorized for the breast cancer combination therapy of Tecentriq

FDA Approves Roche CDx for Breast Cancer Combination Therapy Developed with Celgene

VENTANA PD-L1 (SP142) Assay is a companion diagnostic for Tecentriq + Abraxane, the first immunotherapy regimen approved for breast cancer.
HTG Molecular Diagnostics is expanding its year-old collaboration with Merck KGaA beyond companion diagnostics with a complementary focus on translational programs

HTG Expands Collaboration with Merck KGaA Beyond CDx

HTG's year-old collaboration with Merck KGaA now includes a complementary focus on translational programs as well as companion diagnostics.
Source: KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty Images

Gut Microbiome Promotes Pancreatic Cancer Progression

Pathogenic gut bacteria that migrate to the pancreas via the pancreatic duct shut down the immune system and promote tumor growth
Source: royaltystockphoto/Getty Images

Research Consortium IDs 72 New Genetic Risk Variants for Breast Cancer

Researchers use data from 275,000 women for a genome-wide association study that found seven variants specific to ER-negative breast cancer
BGI Group and the Fred Hutchinson Cancer Research Center have signed a memorandum of understanding committing them to explore cooperative projects in areas including cancer genomics

BGI, Fred Hutch to Partner on Cancer Genomics, Infectious Disease Research

Sequencing giant, research institute also commit to establishing partnerships with hospitals and research institutions in China and Africa.
Qiagen will partner with Health Innovation Manchester to build a precision medicine campus in the U.K. city's health innovation district. The company plans to base a European Centre of Excellence for Precision Medicine and hub for diagnostics development within the next phase of Manchester Science Partnerships' Oxford Road Citylabs campus—a £60 million ($79.4 million)

Qiagen Health Innovation Manchester Partner on Precision Medicine Campus

The campus will house Qiagen’s planned European Centre of Excellence for Precision Medicine and hub for diagnostics development
Figure 1. Potential for variability in molecular diagnostics workflow

The Promise and Challenge of Molecular Diagnostics

Companion diagnostics are bridging the gap between molecular diagnostics and therapeutics, helping to ensure that the right drug is provided to the right patient...
Source: © Mopic - Fotolia.com

Thermo Fisher Lists Its Ion PGM DX System as Class II Clinical Medical Device

Thermo Fisher Scientific completed the listing of its Ion PGM Dx next-generation sequencing (NGS) system with the FDA for clinical use as a class...
Johnson & Johnson’s Janssen Research & Development will use BiomX's XMarker platform to discover microbiome-based biomarkers for inflammatory bowel disease (IBD)

“Good” Bacteria Added to Gut Microbiome Can Combat Food Allergies

Call them the guardians of the gut microbiome: bacteria that are associated with protection against food allergies. Such bacteria, “good” bacteria, have been identified...
Scroll Up